Hurler's syndrome is an inborn error of mucopolysaccharide metabolism leading to premature death in childhood. Allogeneic hematopoietic SCT can achieve long-term survival by correcting the enzymatic deficiency. In an attempt to improve long-term engraftment and to reduce regimen-related toxicity (RRT), a prospective multicenter approach was initiated in Germany using a fludarabinebased radiation-free preparative regimen. Between 2001 and 2008, 12 children were enrolled. Median age at SCT was 14 months (range, 4-31 months). The conditioning regimen contained fludarabine, BU, melphalan and antithymocyte globulin. CD34 positively selected PBSC were used in 10 children with a matched unrelated donor. Median cell dose was 24.6 Â 10 6 CD34 þ cells per kg (range 10.0-54.8). Two children with a matched sibling donor received non-manipulated BM. Donor lymphocyte infusions were given in 6/12 children for mixed hematopoietic chimerism. At a median follow-up of 29 months (range 2-85 months), all children engrafted and have either stabilized or improved neurological function. In total, 12/12 patients showed donor-derived engraftment with 9/12 having full and 3/12 having mixed hematopoiesis. One developed acute GVHD Xgrade II. RRT Xgrade II was observed in two patients.
Introduction
Hurler's syndrome (MPS IH) is an autosomal recessive inborn error of metabolism because of a deficiency of a-Liduronidase activity. Clinical manifestations include hepatosplenomegaly, progressive mental retardation, hydrocephalus, cardiac disease with coronary insufficiency, airway compromise, vision and hearing impairment, and severe skeletal deformations. Untreated patients develop progressive mental retardation and multisystem morbidity with a median life expectancy of 5 years. 1 To date, hematopoietic SCT from an allogeneic donor represents the only proven therapy that can prolong survival and either reverse or stabilize disease manifestations. [2] [3] [4] However, over the years it has been shown that these patients are especially prone to two complications of allo-SCT: graft failure and regimenrelated, especially pulmonary, toxicity (RRT). Historically, as reported by the North American Storage Disease Collaborative Study Group experience, the likelihood of graft failure was 15% from an HLA fully matched sibling donor and up to 37% when an unrelated donor was used. 2, 3 Although the preparative regimens of these studies varied, both over time and between transplant centers, most patients received a combination including BU and CY plus/minus T-cell depletion of the graft. To address these problems, we designed the MPS-HCT 2005 protocol with the following objectives in mind: as the combination of CY with BU resulted in significant RRT, including especially the lungs and heart, we substituted CY with fludarabine, a potentially less toxic immunosuppressive agent that had the potential to mediate sustained engraftment after allo-SCT. Melphalan was chosen for additional myeloablation because of its low cardiotoxicity. To further reduce pulmonary toxicity and to avoid GVHD as much as possible, all patients with matched unrelated donor or mismatched family donor received a highly T-cell-depleted graft and all patients including matched family donors received antithymocyte globulin (ATG). To promote engraftment, high doses of at least 10 Â 10 6 CD34 cells per kg were given according to the 'megadose' concept developed for haploidentical transplantation. 5 For decreasing donor chimerism, small doses of donor lymphocyte infusions (DLI) were included in the treatment concept.
The goal of this study was to determine whether a combination of 180 mg/m 2 fludarabine, weight-adjusted BU and 140 mg/m 2 melphalan, combined with a T-celldepleted graft and T-cell addback for decreasing donor chimerism, could provide sustained engraftment after allo-SCT from related and unrelated donors without an increased incidence and severity of transplant-related complications.
Patients and methods
Patients, donors and conditioning After a pilot phase starting in 2001, MPS-SCT 2005 was initiated at Hannover Medical School as a prospective multicenter approach. 6 As a phase 2 study, the protocol was approved by the institutional review board and then distributed to other German centers willing to transplant children with inborn errors of metabolism. A total of 12 consecutive children were enrolled. The parents of each patient provided written informed consent before enrollment. Patients and potential donors underwent 4-digit high-resolution typing for HLA class I (A, B and C) and class II (DRB1 and DQ). All children had either beginning or manifest clinical features typically associated with the disease. Definitive diagnosis was made on the basis of a deficient activity of a-L-iduronidase. Urinary excretion of the glycosaminoglycans dermatan and heparan sulfate was elevated. One patient was diagnosed shortly after birth because he had an affected cousin. Donors having one allele mismatch (match 9/10) were considered to be matched donors. The children enrolled in the main protocol (8/12 patients) received a fully myeloablative preparative regimen consisting of intravenous BU (Busulfex, weightadjusted dose according to Nguyen et al. , day À5) and ATG (ATG rabbit Fresenius at either 10 mg/kg per day, days À3 to day À1 in the case of a matched family donor transplant, total dose 30 mg/kg or 20 mg/kg per day, days À3 to day À1 in the case of an unrelated donor transplant, total dose 60 mg/kg), followed by hematopoietic cell infusion. The first four patients transplanted (4/12) received their treatment according to the pilot phase protocol, which consisted of 40 mg/kg ATG, intravenous BU and fludarabine. Melphalan was added when starting with patient 3.
Engraftment
Engraftment was defined as the first of two consecutive days with an absolute neutrophil count of at least 500/ml. Graft failure was diagnosed with an absolute neutrophil count o500/ml at day 30. Autologous recovery was defined as less than 10% donor chimerism. Hematopoietic chimerism was assessed for the first time once an absolute neutrophil count of 500/ml was achieved. Chimerism was documented by in situ Y chromosome hybridization of blood samples in sex-mismatched donor/recipient pairs and by analysis of a variable number of tandem repeat polymorphisms, as well as by microsatellite analysis of blood samples in the case of sex-matched pairs. Chimerism was defined as complete when donor-derived hematopoiesis exceeded or equalled 95% and as mixed when an engraftment between 10 and 94% was achieved. In case donor-derived hematopoiesis dropped below 95% after transplant, donor CD3 cells were given starting at a dose of 2.5 Â 10 4 /kg if no clinical acute GVHD (aGVHD) was present. Consecutive doses were given at a minimal interval of 4 weeks.
Prophylaxis and grading of GVHD All apheresis products were positively selected for CD34 þ cells using the magnetic CliniMACS sorting device (Miltenyi Biotec, Bergisch Gladbach, Germany). Apart from ATG during the preparative regimen, no additional GVHD prophylaxis was given except in patient no. 8 8 who received mycophenolate mofetil for 2 months because of a residual CD3 cell dose that exceeded the limit considered safe without immunosuppression. The severity of aGVHD was scored using standard criteria. 9 The two children transplanted with non-manipulated BM received a standard GVHD prophylaxis consisting of CsA and short-term MTX.
Results

Patients, donors and regimen-related toxicity
Between March 2001 and January 2008, 12 consecutive children with Hurler's syndrome underwent SCT. Median age at SCT was 14 months (range, 4-31 months). In total, 10/12 patients received CD34 þ cells enriched from PBSC (nine from unrelated donors, two from their mothers). Two children were transplanted with a non-manipulated BM graft from their sisters. Pre-transplant characteristics are summarized in Table 1 . Acute regimen-related toxicity was rated according to the National Cancer Institute common toxicity criteria. Two out of 12 children had extrahematopoietic toxicity Xgrade II during their post-transplant course that was related to the transplant procedure. One (child no.2) developed subdural hemorrhage on day þ 6 after SCT and required surgical intervention. Child no.12 experienced veno-occlusive disease rapidly responding to defibrotide. Both children are alive and well. Two patients had complications not specifically related to the preparative regimen. One patient no. 10 10 with pre-existing dilatative cardiomyopathy had a severe adverse reaction to a platelet transfusion resulting in pulmonary edema and consecutive temporary cardiac insufficiency requiring pressor support in our intensive care unit. Patient no. 9 had a rapid progression of his hydrocephalus (no bleeding, no infection) within the first week after transplant requiring the placement of a ventriculo-peritoneal shunt. He is suffering from only partially resolved cortical blindness.
Engraftment and outcome
At a median follow-up time of 29 months (range 2-85 months), all 12 patients (100%) are alive, well and engrafted. Neutrophil engraftment occurred at a median of 18 days (range: 10-28 days). Platelet (platelet count 450 000/ml) and red cell (reticulocytes 420/nl) recovery were observed at a median of 23 days (range: 9-46 days) /kg as intended by the protocol. In addition, it was associated with an adenovirus enteritis diagnosed within 1 day after adoptive transfer. The episode resolved after prolonged systemic immunosuppressive therapy and a single administration of mesenchymal stem cells from the original donor. Post-transplant results are summarized in Table 2 .
Discussion
The goal of this study was to reduce historically reported RRT without increasing the rate of graft rejection. Although SCT represents an effective treatment for children suffering from MPS IH, the procedure carries a significant risk of morbidity and mortality. Apart from non-disease-specific early and late effects associated with preparative regimens necessary to facilitate engraftment, more Hurler-specific RRT has been reported. GVHD rates reached 30-55% and accounted for up to 50% of transplantation-associated mortality. 3, 11 In addition, graft failure has been observed in 28-37% of such patients despite the use of TBI. 2, 11, 12 These historic experiences were the rationale for launching a German multicenter approach. All 12 consecutive patients transplanted according to this strategy are alive, engrafted and without neurological disease progression. Comparing our data with these historical data, however, is not completely fair, as HLA typing techniques and supportive care have become much more sophisticated over time. Furthermore, children have been transplanted at a younger age in more recent years. In our series, median age at transplantation was 14 months. The group from Lyon published 27 patients receiving nonmanipulated BM after BU/CY and ATG. In total, 21 patients (78%) are engrafted, alive and well. Remarkably low GVHD rates were reported in spite of the fact that the median age at transplantation was 25 months. 13 Boelens et al.
14 retrospectively analyzed data of 146 MPS IH patients who were retrieved from the European Blood and Marrow Transplantation database. This very thorough report retrospectively identified T-cell depletion of the graft and reduced-intensity regimens with an increased rate of graft failure.
It is important to note that the protocol for this German multicenter approach was initiated before the cord blood results from Duke University were published in 2004. These impressive results must currently be considered to be the 'gold standard' for transplanting children with MPS IH. The event-free survival rate was 85%. aGVHD rates 4grade II necessitating systemic steroid therapy reached 25%. Transplant-related deaths were caused mainly by infectious complications. No lung toxicity was reported. 15 Being aware of these results and the historically unsatisfying results of T-cell depletion, the German multicenter approach uses strong myeloablation and immunosuppression with BU/Fludarabine/Melphalan and ATG as a preparative regimen. The use of CY and TBI was purposefully avoided. On a molar basis and relative to other toxicities, CY was shown to be the most immunosuppressive anticancer drug of any type. 16 Given at very high doses (200 mg/kg or greater) as a single agent, as used in preparation regimens for BMT, CY rarely causes cumulative damage to the BM, reflecting its stem cell-sparing properties. 17 Therefore, this compound has been used primarily in BMT for its immunosuppressive and antileukemic properties. Dose limiting, however, seems to be its cardiac toxicity. 18 Fludarabine, in contrast, is a purine analog with known inhibitory effects on lymphocyte proliferation. This drug has shown very little extramedullary toxicity in dose ranges between 90 and 125 mg/m 2 , although side effects involving the central nervous system are known to occur at higher doses. 19, 20 Fludarabine, importantly, is not known to deplete the patient's glutathion pool. This might be of increasing importance in patients entering SCT with preexisting organ damage. In contrast to CY, BU has a potent myeloablative effect. In combination, these two drugs are the basis of the most commonly used radiation-free preparative regimens in BMT. 21 Unfortunately, the combination of CY and BU is prone to mediate endothelial damage of the small liver venules, resulting in venous occlusive disease and pulmonary injury. 22 Melphalan was added during the pilot phase of the protocol, after the first patients developed mixed chimerism. It is difficult to draw conclusions after 12 patients; however, one might speculate that the addition of Melphalan was not necessary. This might be especially true if targeted BU levels were used.
As a graft source, we predominately used 'T-celldepleted' PBSC. T-cell depletion was achieved by CD34 cell-positive selection. This approach was chosen on the basis of the German experience in using high numbers of CD34 þ cells for haploidentical transplantation. This concept has proven to be highly efficacious in preventing graft rejection for transplantation across HLA barriers (haploidentical transplantation). 5, 23, 24 However, it is important to state that the German multicenter protocol MPS-HCT 2005 includes the following algorithm for selecting a graft:
(1) Non-manipulated BM from a matched genoidentical sibling donor (this reflects the recommendation of the European Group for Blood and Marrow Transplantation (EBMT) guidelines), (2) CD34 þ selected PBSC from a high resolution (HLA-class I and II) typed matched unrelated or family donor, (3) A single 6/6 matched cord blood unit, if the cell dose exceeds 43.0 Â 10 7 /kg of body weight, and (4) CD34 þ selected PBSC from a haploidentical parental family donor. There might have been a rationale for using a less immunosuppressive preparative regimen for patients having a matched family donor. However, this would have added an additional confounding factor making the interpretation of data retrieved from a small patient cohort even more complicated. A significant part of our patients (6/12) developed mixed hematopoietic chimerism after transplant. According to the protocol, DLI were given when donor-derived peripheral leukocytes dropped below 95%. It is difficult to judge whether this intervention was necessary. However, given the historically poor results of T-cell depletion and lacking tools to predict the dynamics of a drop in donor-derived hematopoiesis, we recommended intervention early. The decline of chimerism was halted in all patients; however, only three patients converted to full donor chimerism again. Except for one patient who received a higher than recommended initial T-cell dose also associated with an adenovirus colitis, none of the DLI recipients developed clinical GVHD.
One might argue that 'T-cell depletion' is counterproductive if there is a need to give back T cells later after transplant. However, it is important to take into account that the effects of donor-derived T cells are very distinctive depending on whether they act early or delayed after transplant. T cells can trigger significant GVHD early after transplantation, a phenomenon that is associated with significant inflammatory pressure caused in part by the endothelial damage because of the preparative regimen. Adding T cells later can bring the desired effect regarding engraftment but decreases the risk of GVHD. In addition, T cells are important contributors to pulmonary toxicity and T-cell depletion can reduce this toxicity, which is especially relevant for Hurler patients. [25] [26] [27] Some centers might be reluctant to give pre-emptive DLI because of its potential to trigger GVHD. The reported series represents an investigational approach. Outside a specific research protocol, transplant procedures for Hurler patients should follow the current guidelines available on the Inborn Errors Working Party (IEWP) page of the EBMT website. However, transplanting these children within clinical trials at specialized HCT institutions will certainly help minimize RRT. We consider our approach as a step in this direction.
Purposefully, we did not include long-term neuropsychological data in this report. As patient numbers are small, the transplant team from Utrecht, The Netherlands, has initiated a European effort for standardized neurocognitive follow-up examination for this special group of patients after transplantation. The German children will be part of this initiative and results will be published separately.
